title: Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.
abstract: OBJECTIVE
  Different Human Papilloma Virus (HPV) tests are currently used. An integrated comparison of the Amplicor, Cobas4800, PreTect HPV-Proofer and APTIMA HPV tests has not been done.
  
  
  METHODS
  We compared the high-risk HPV detection power of these HPV tests in 528 consecutive population-based follow-up Liquid-Based Cytology samples (LBC) after ASCUS/LSIL index cytology. Their sensitivity and specificity to detect HPV in LBC, their predictive values of histopathologic CIN2-3 in follow-up punch biopsies and CIN2-3 regression in the subsequent cones was assessed. The HPV subtypes detected by the Linear Array genotyping-test (LA), PreTect HPV-Proofer and Cobas4800 were also compared. The follow-up histopathology was consensus expert-reviewed and Ki67/p16-supported. The predictive values of the HPV results in LBC by the different tests for presence of CIN2-3 in follow-up biopsies, and regression in subsequent cones, was assessed.
  
  
  RESULTS
  Amplicor, Cobas4800 and APTIMA show good agreement for HPV-positivity/negativity. PreTect HPV-Proofer has many discrepancies versus any of the other methods. The sensitivities for Amplicor, Cobas4800 and APTIMA to detect CIN2-3 were very high (96-100%), but rather low for PreTect HPV-Proofer (53%). Specificity in case of CIN1 or less in follow-up biopsies of Amplicor and Cobas4800 is lower than APTIMA and highest for PreTect HPV-Proofer. HPV subtyping by LA agreed in 90% with Cobas4800 but 70% with PreTect HPV-Proofer.
  
  
  CONCLUSIONS
  The Amplicor, Cobas4800 and APTIMA give comparable results but PreTect HPV-Proofer differs from the other tests, with low sensitivity but higher specificity. None of the methods predicted regression of CIN2-3.
authors.affiliation: Department of Pathology, Stavanger University Hospital, Stavanger, Norway.
authors.forename: Irene T
authors.initials: IT
authors.lastname: Ovestad
authors.forename: Undis
authors.initials: U
authors.lastname: Vennestrøm
authors.forename: Liv
authors.initials: L
authors.lastname: Andersen
authors.forename: Einar
authors.initials: E
authors.lastname: Gudlaugsson
authors.forename: Ane Cecilie
authors.initials: AC
authors.lastname: Munk
authors.forename: Anais
authors.initials: A
authors.lastname: Malpica
authors.forename: Weiwei
authors.initials: W
authors.lastname: Feng
authors.forename: Feja
authors.initials: F
authors.lastname: Voorhorst
authors.forename: Emiel A M
authors.initials: EA
authors.lastname: Janssen
authors.forename: Jan P A
authors.initials: JP
authors.lastname: Baak
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D003127:Colposcopy; D005260:Female; D005500:Follow-Up Studies; D060005:Genotyping Techniques; D006801:Humans; D008875:Middle Aged; D009365:Neoplasm Regression, Spontaneous; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification*; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000473:pathology / Q000821:virology*